Insight

The potential of precision medicine in gynaecologic cancers – ESMO

Photo from ESMO/LinkedIn

Jun 25, 2024, 03:43

The potential of precision medicine in gynaecologic cancers – ESMO

The European Society for Medical Oncology (ESMO) shared on LinkedIn:

“ESMOGynae24: The combination of comprehensive genomic profiling and ranking genomic alterations using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

After discussion in a Molecular Tumour Board, 22 patients received molecularly guided treatment options showcasing the potential of precision medicine in gynaecologic cancers, where ESMO is showing its commitment to facilitating patients’ access to optimal cancer care.”

Source: ESMO/LinkedIn

cancer ESCAT ESMO ESMO Scale for Clinical Actionability of molecular Targets ESMOGynae24 European Society for Medical Oncology gynaecologic cancers Molecular Tumour Board OncoDaily Oncology Precision Medicine

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

Special Coverage